Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer

Video

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

The concept of eventually replacing trastuzumab (Herceptin) with an engineered and modified antibody is very intriguing, Pegram says. If ongoing work with FC-engineered antibodies comes to fruition, they could very well replace the gold standard. Ado-trastuzumab emtansine (T-DM1; Kadcyla) garnered much attention at the 2018 San Antonio Breast Cancer Symposium, showing promise in the adjuvant setting.

Moreover, second-generation antibody-drug conjugates look promising, Pegram adds. Trastuzumab deruxtecan (DS-8201) has shown impressive activity against HER2-positive tumors across multiple disease subtypes. The compound SYD985 has also been encouraging. Notably, both of these compounds also show benefit in HER2-low expressing tumors, in cases that would have otherwise been considered HER2-negative.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,